GSK N Stock Overview
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£775.31 |
| 52 Week High | UK£775.31 |
| 52 Week Low | UK£624.60 |
| Beta | 0.33 |
| 11 Month Change | 3.31% |
| 3 Month Change | 3.23% |
| 1 Year Change | n/a |
| 33 Year Change | -30.39% |
| 5 Year Change | -27.62% |
| Change since IPO | -3.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| GSK N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -0.3% |
| 1Y | n/a | -14.8% | -1.8% |
Return vs Industry: Insufficient data to determine how GSK N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how GSK N performed against the MX Market.
Price Volatility
| GSK N volatility | |
|---|---|
| GSK N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.2% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: GSK N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine GSK N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 70,212 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
GSK plc Fundamentals Summary
| GSK N fundamental statistics | |
|---|---|
| Market cap | Mex$1.47t |
| Earnings (TTM) | Mex$65.91b |
| Revenue (TTM) | Mex$821.90b |
22.3x
P/E Ratio1.8x
P/S RatioIs GSK N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSK N income statement (TTM) | |
|---|---|
| Revenue | UK£31.31b |
| Cost of Revenue | UK£8.65b |
| Gross Profit | UK£22.67b |
| Other Expenses | UK£20.15b |
| Earnings | UK£2.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 72.39% |
| Net Profit Margin | 8.02% |
| Debt/Equity Ratio | 119.4% |
How did GSK N perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield99%
Payout RatioDoes GSK N pay a reliable dividends?
See GSK N dividend history and benchmarks| GSK dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Jan 09 2025 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 56 days |
Does GSK N pay a reliable dividends?
See GSK N dividend history and benchmarks